Core Viewpoint - Green Leaf Pharmaceutical (02186) announced a capital injection agreement involving multiple parties, which will enhance its financial position and ownership structure in its subsidiary, Nanjing Green Leaf [1] Group 1: Capital Injection Details - On January 26, 2026, Shenzhen Green Leaf, Nanjing Xinshi, Nanjing Xinan, Ningbo Xinda, and Nanjing Green Leaf entered into a capital injection agreement, totaling RMB 285 million [1] - Following the completion of the capital injection, the ownership of Nanjing Green Leaf will be held by Shenzhen Green Leaf (70.01%), Nanjing Xinshi (23.34%), Nanjing Xinan (4.32%), and Ningbo Xinda (2.33%) [1] Group 2: Rights and Agreements - A series of further transactions have been established regarding the capital injection, including an equity option agreement that allows Yantai Green Leaf to require the investors to sell their respective stakes in Nanjing Green Leaf [1] - The equity option agreement also grants the investors the right to request Yantai Green Leaf to repurchase their stakes under certain conditions [1] Group 3: Company Focus - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sales of pharmaceuticals, with a focus on cancer treatment [1] - Yantai Green Leaf and Shenzhen Green Leaf are wholly-owned subsidiaries of the company, primarily involved in investment holding activities [1]
绿叶制药：南京绿叶获2.85亿元注资